Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, multicenter, open-label, parallel-group study comparing adalimumab 40 mg s.c. eow [every other week] versus infliximab 3 mg/kg i.v. every 6 weeks in rheumatoid arthritis patients with unsustainable clinical response to infliximab 3 mg/kg every 8 weeks.

Next Previous
X
Search
Trial Profile

Randomised, multicenter, open-label, parallel-group study comparing adalimumab 40 mg s.c. eow [every other week] versus infliximab 3 mg/kg i.v. every 6 weeks in rheumatoid arthritis patients with unsustainable clinical response to infliximab 3 mg/kg every 8 weeks.

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Infliximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms SWITCH

    • Most Recent Events

    • 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
    • 25 Aug 2009 Planned end date changed from 1 Sep 2008 to 1 Jun 2009 as reported by ClinicalTrials.gov.
    • 18 Aug 2009 Biomarkers information updated

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top